The question "Amgen Tepezza" likely refers to Tepezza (teprotumumab-trb) and its connection to Amgen. Tepezza is a medication approved for the treatment of thyroid eye disease (TED). While Amgen is a prominent biopharmaceutical company, Horizon Therapeutics, now an Amgen subsidiary, developed and markets Tepezza.
What is Tepezza?
Tepezza is an insulin-like growth factor 1 receptor (IGF-1R) antagonist [1]. It works by targeting the underlying cause of thyroid eye disease, which is an autoimmune condition that affects the tissues around the eye [1]. The medication is administered intravenously [1].
What is Thyroid Eye Disease?
Thyroid eye disease (TED) is a chronic, progressive autoimmune condition affecting the orbits of the eyes [1]. It can cause symptoms such as bulging eyes (proptosis), double vision (diplopia), eye pain, redness, swelling, and in severe cases, vision loss [1]. TED is associated with Graves' disease but can occur independently [1].
Who Developed and Markets Tepezza?
Tepezza was developed by Horizon Therapeutics [2]. In October 2023, Amgen completed its acquisition of Horizon Therapeutics [3]. Therefore, Tepezza is now part of Amgen's portfolio.
How Effective is Tepezza?
Clinical trials have demonstrated Tepezza's efficacy in treating TED. In the Phase 3 OPTIC trial, a significant proportion of patients treated with Tepezza experienced meaningful improvements in proptosis, diplopia, and overall clinical meaningfulness compared to placebo [1]. Studies have shown that Tepezza can reduce eye bulging, improve double vision, and alleviate other symptoms of TED [1].
What are the Side Effects of Tepezza?
Common side effects associated with Tepezza treatment include muscle spasms, nausea, diarrhea, hair loss, decreased appetite, and dry skin [1]. Less common but serious side effects may include infusion-related reactions and hyperglycemia [1]. Patients with pre-existing diabetes should be closely monitored for blood sugar control during treatment [1].
How is Tepezza Administered?
Tepezza is administered through an intravenous infusion [1]. The typical treatment regimen involves infusions every three weeks for a total of six infusions [1].
Is Tepezza Still Available?
Yes, Tepezza is an approved medication and is available for patients diagnosed with thyroid eye disease [1].
Sources
1. https://www.drugpatentwatch.com/drug/tepezza
2. https://www.horizontherapeutics.com/our-products/tepezza
3. https://www.amgen.com/newsroom/press-releases/2023/10/amgen-completes-acquisition-of-horizon-therapeutics-plc